BR112021006784A2 - Construtos de anticorpo que se ligam a 4-1bb e antígenos associados a tumor e usos dos mesmos - Google Patents

Construtos de anticorpo que se ligam a 4-1bb e antígenos associados a tumor e usos dos mesmos Download PDF

Info

Publication number
BR112021006784A2
BR112021006784A2 BR112021006784-1A BR112021006784A BR112021006784A2 BR 112021006784 A2 BR112021006784 A2 BR 112021006784A2 BR 112021006784 A BR112021006784 A BR 112021006784A BR 112021006784 A2 BR112021006784 A2 BR 112021006784A2
Authority
BR
Brazil
Prior art keywords
sequence
chain variable
antibody
variable domain
antigen
Prior art date
Application number
BR112021006784-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Daniel T. Patton
Brandon Clavette
Anna Von Rossum
Duncan Browman
Peter Wing Yiu Chan
Danny Chui
Robert William Gene
Sukhbir Singh Kang
Sylwia Jancowski
Patricia Zwierzchowski
David M. Mills
Thomas Spreter Von Kreudenstein
Gesa Volkers
Dunja UROSEV
Lee Freiburger
Zhuang Duan
Elizabeth Halvorsen
Harsh Pratap
Original Assignee
Zymeworks Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymeworks Inc. filed Critical Zymeworks Inc.
Publication of BR112021006784A2 publication Critical patent/BR112021006784A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112021006784-1A 2018-10-10 2019-10-10 Construtos de anticorpo que se ligam a 4-1bb e antígenos associados a tumor e usos dos mesmos BR112021006784A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862744059P 2018-10-10 2018-10-10
US62/744,059 2018-10-10
PCT/CA2019/051448 WO2020073131A1 (en) 2018-10-10 2019-10-10 Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof

Publications (1)

Publication Number Publication Date
BR112021006784A2 true BR112021006784A2 (pt) 2021-09-21

Family

ID=70164178

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021006784-1A BR112021006784A2 (pt) 2018-10-10 2019-10-10 Construtos de anticorpo que se ligam a 4-1bb e antígenos associados a tumor e usos dos mesmos

Country Status (10)

Country Link
US (1) US20230052369A1 (https=)
EP (1) EP3864051A4 (https=)
JP (1) JP7596263B2 (https=)
KR (1) KR20210076918A (https=)
CN (2) CN112996809A (https=)
AU (1) AU2019356806B2 (https=)
BR (1) BR112021006784A2 (https=)
CA (1) CA3113539A1 (https=)
MX (1) MX2021004058A (https=)
WO (1) WO2020073131A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021207827A1 (en) * 2020-04-15 2021-10-21 Zymeworks Inc. Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
MX2022013944A (es) * 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
CN112794911B (zh) * 2021-04-14 2021-08-03 上海偌妥生物科技有限公司 人源化抗叶酸受体1抗体及其应用
CA3216342A1 (en) * 2021-04-23 2022-10-27 Hassan ISSAFRAS Anti-gpc3 antibodies, multispecific antibodies and methods of use
CN116769041A (zh) * 2022-03-10 2023-09-19 合肥瀚科迈博生物技术有限公司 靶向msln和4-1bb的双特异性抗体及其应用
EP4584300A1 (en) * 2022-09-06 2025-07-16 TJ Biopharma (Shanghai) Co., Ltd. Multispecific constructs and uses thereof
US20240190958A1 (en) * 2022-10-18 2024-06-13 Tubulis Gmbh Novel antibody drug conjugates with novel napi2b antibodies, therapeutic methods and uses thereof
WO2025131027A1 (en) * 2023-12-21 2025-06-26 Lanova Medicines Development Co., Ltd. Anti-slc34a2/anti-4-1bb antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402865B2 (en) * 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
EP3593812A3 (en) * 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
AU2017252233A1 (en) * 2016-04-22 2018-11-15 Alligator Bioscience Ab Novel bispecific polypeptides against CD137
KR20240000650A (ko) * 2016-10-19 2024-01-02 인벤라 인코포레이티드 항체 구조물
IL268836B2 (en) * 2017-02-24 2024-04-01 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof

Also Published As

Publication number Publication date
CA3113539A1 (en) 2020-04-16
KR20210076918A (ko) 2021-06-24
JP7596263B2 (ja) 2024-12-09
JP2022504826A (ja) 2022-01-13
AU2019356806A1 (en) 2021-05-27
EP3864051A4 (en) 2022-11-23
EP3864051A1 (en) 2021-08-18
WO2020073131A1 (en) 2020-04-16
MX2021004058A (es) 2021-06-04
AU2019356806B2 (en) 2026-03-05
CN121758617A (zh) 2026-03-31
US20230052369A1 (en) 2023-02-16
CN112996809A (zh) 2021-06-18

Similar Documents

Publication Publication Date Title
AU2019356806B2 (en) Antibody constructs binding 4-1BB and tumor-associated antigens and uses thereof
JP2022137054A (ja) ＮＫｐ４６結合タンパク質の可変領域
CN110325209A (zh) 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
HK1215035A1 (zh) 人源化抗cd134(ox40)抗體及其應用
CN111542543A (zh) 针对pd-l1的抗体及其变体
JP2021510064A (ja) 細胞傷害誘導治療剤
JP2023524102A (ja) Ａｂｃｂ５に特異的な抗体およびその使用
US20230357398A1 (en) Novel human antibodies binding to human cd3 epsilon
EP4155318A1 (en) Bispecific antibody and use thereof
JP2022540620A (ja) 胸腺間質性リンパ球新生因子（ｔｓｌｐ）受容体シグナル伝達に干渉する薬剤
CN115461367A (zh) 抗ox40抗体及其用途
CN110172099A (zh) 抗lag-3人源化单克隆抗体分子，抗原结合片段及其医药用途
CN116178553B (zh) 针对人b7-h3的抗体及其变体
WO2024113099A1 (en) Protease cleavable recombinant bispecific antibodies and compositions and uses thereof
US20230265202A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
CN111788229A (zh) Csf1r结合剂
JP2024542914A (ja) ヒトｃｘｃｌ１６抗体およびその使用
CN115698066A (zh) 抗cd47抗体及其用途
KR20260038271A (ko) 항-trop2 항체
WO2025259563A2 (en) Anti-cd3 constructs and uses thereof
KR20250154601A (ko) Nkg2a와 pd-l1에 결합하는 작용제 및 이의 용도
KR20260044233A (ko) 항-ceacam5 항체 약물 접합체

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ZYMEWORKS INC. (CA) ; ZYMEWORKS BC INC. (CA)

B25G Requested change of headquarter approved

Owner name: ZYMEWORKS BC INC. (CA)